サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1800960

多発性硬化症治療薬の市場レポート：薬物、薬物タイプ、投与経路、流通チャネル、地域別、2025年～2033年

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 120 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
多発性硬化症治療薬の市場レポート：薬物、薬物タイプ、投与経路、流通チャネル、地域別、2025年～2033年
出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 120 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多発性硬化症治療薬市場規模は2024年に279億米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに388億米ドルに達し、2025～2033年の成長率（CAGR）は3.52％になると予測しています。

多発性硬化症（MS）は、脊髄や脳の神経細胞の脱髄、軸索切断、神経変性を引き起こす可能性のある、免疫介在性の慢性炎症性疾患を指します。一般的に用いられる治療法には、注射薬、経口薬、点滴薬、筋弛緩薬、抗うつ薬、理学療法などがあります。注射薬にはインターフェロンβやグラチラマー酢酸塩などがあり、皮下や筋肉内に投与されます。内服薬にはフマル酸ジメチル、テリフルノミド、クラドリビンなどがあり、点滴治療にはオクレリズマブ、ナタリズマブ、アレムツズマブなどがあり、これらは静脈内に投与されます。これらの薬は、再発の頻度を最小限に抑え、患者の心拍数と血圧をコントロールするために、症状の管理を助ける。

再発寛解型多発性硬化症（RRMS）、原発性進行性MS（PPMS）、二次性進行性MS（SPMS）、進行性再発性MS（PRMS）の世界の有病率の増加は、市場の成長を促進する重要な要因の1つです。さらに、このような病気にかかりやすい老年人口が増加していることも、市場の成長を後押ししています。ヘルスケアプロバイダーは、自己免疫発作を制御し、MSを患う患者の再発を予防する免疫抑制剤を広く使用しています。さらに、MSの効果的な治療のための革新的なモノクローナル体、免疫調節剤、免疫抑制剤、インターフェロンの開発など、さまざまな技術的進歩が他の主要な成長促進要因として作用しています。これとは別に、先進国、新興国を問わず、政府が大衆の間で利用可能な治療法に関する認識を高めるためのキャンペーンを展開しており、これがひいては市場に明るい展望をもたらしています。その他の要因としては、広範な研究開発（R&D）活動、ヘルスケアインフラの改善などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の多発性硬化症治療薬市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19が世界の多発性硬化症治療薬市場に与えた影響は？
  • 主要な地域市場とは？
  • 薬剤別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 投与経路別の市場内訳は？
  • 販売チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の多発性硬化症治療薬市場の構造と主要企業は？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬物別

  • 免疫調節薬
    • 主な種類
      • コパキソン
      • アボネックス/プレグリディ
      • ギルネヤ
      • ティサブリ
      • ベタセロン/エクスタビア
      • テシフィデラ
      • レビフ
      • アンピラ
  • 免疫抑制剤
    • 主な種類
      • アウバジオ
      • レムトラダ
      • オクレリズマブ
      • ジンブリタ

第7章 市場内訳：薬剤タイプ別

  • 生物学的製剤
  • 低分子医薬品

第8章 市場内訳：投与経路別

  • 経口
  • 注射剤
  • 静脈内

第9章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2024
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million USD), 2025-2033
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player
目次
Product Code: SR112025A2571

The global multiple sclerosis therapies market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 38.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Drug:

  • Immunomodulators
    • Copaxone
    • Avonex/Plegridy
    • Gilneya
    • Tysabri
    • Betaseron/Extavia
    • Tecifidera
    • Rebif
    • Ampyra
  • Immunosuppressants
    • Aubagio
    • Lemtrada
    • Ocrelizumab
    • Zinbryta

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis